Health ProductsPublic Communication

Archived – Possible Association Between RITUXAN® (Rituximab) and the Recurrence of Hepatitis B – Hoffmann-La Roche Limited – For the Public

· Published by Health Canada · Official notice

Details

Alert type: Public Communication
Category: Biologic/vaccine
Issue: Important Safety Information
Audience: General Public
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Hoffmann-La Roche Limited.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

[Text of letter begins]

Public Advisory
Health Canada Endorsed Important Safety Information on RITUXAN (rituximab)

July 30, 2004

Subject: Possible association between RITUXAN and the recurrence of hepatitis B

Hoffmann-La Roche Limited, in consultation with Health Canada, has informed Canadian healthcare professionals of important new safety information concerning RITUXAN (rituximab). This drug is used to treat some types of lymphomas (cancers of the lymph nodes) either alone or with chemotherapy. Please note the following new safety information for the use of RITUXAN:

  • Very rare cases of recurrence of hepatitis B virus infection have been reported, occasionally leading to liver failure and death. Most of these cases occurred in patients who were also receiving chemotherapy.
  • Patients at risk for hepatitis B infection should have a blood test before starting RITUXAN to determine if they are carrying or have had a previous infection with the hepatitis B virus. Patients in doubt of their risk for hepatitis B should talk to their Health Care Provider.
  • Carriers of the hepatitis B virus and patients who have previously been infected with hepatitis B should be closely monitored for signs and symptoms of recurrence of active hepatitis B infection for up to a year after RITUXAN therapy.

Hoffmann-La Roche Limited has continued to gather information on the safety and efficacy of RITUXAN since RITUXAN was introduced to the market.

If hepatitis B infection re-occurs, RITUXAN and any associated chemotherapy should be discontinued and appropriate treatment should be prescribed.

Signs and symptoms of hepatitis B include:

  • yellowing of the skin or eyes (jaundice)
  • feeling of sickness
  • tiredness
  • loss of appetite
  • joint pain
  • abdominal pain

Patients who experience any of these symptoms should contact their physician immediately.

This advisory is in addition to a letter issued to healthcare professionals discussing the above-mentioned safety information. This letter can be accessed at Health Canada's web site at: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2004/index-eng.php

The identification, characterization, and management of marketed health product-related adverse reactions are dependent on the active participation of healthcare professionals in adverse reaction reporting programmes. Any recurrences of hepatitis B virus infection or other serious and/or unexpected adverse reactions in patients receiving RITUXAN should be reported to Hoffmann-La Roche Limited or Health Canada at the following addresses:

Hoffmann-La Roche Limited
Drug Information and Safety Department
2455 Meadowpine Boulevard
Mississauga, ON L5N 6L7
or call toll-free at 1-888-762-4388

Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Health Canada
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca

For other inquiries: please refer to contact information.

The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

original signed by

Lorenzo Biondi
Vice President,
Medical and Regulatory Affairs

[Text of letter ends]

 

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime